|
 |
 |
The recent emergence of novel C diff strains (BI/NAP1) that overproduce the toxins associated with active disease and are increasingly resistant to antibiotics has raised interest in developing new treatment strategies. While metronidazole and oral vancomycin remain the treatments for first-time CDAD, reports of increasing failure and relapse have drawn attention to the need for updated treatment strategies, including improvements in appropriate use of current antibiotics and development of new treatment options.
Agents in late stage development include: nitazoxanide, Xifaxan, tolevamer-K-Na, and antibodies to the disease-causing toxins that C diff produces.
|
|
|
